Latest News
Gedea Biotech selected for prestigious grant funding from the European Innovation Council, EIC
Yesterday, the EIC announced that Gedea Biotech has been selected for the €2.5M EIC Accelerator grant for the continued development and…
About pHyph
pHyph is a CE-marked, antibiotic-free vaginal tablet approved under the EU Medical Device Regulation (MDR) for the treatment of bacterial vaginosis (BV) and for promoting a healthy vaginal microbiome. By restoring the vaginal environment and supporting beneficial lactobacilli, pHyph provides an innovative alternative to conventional treatments. The product is developed by Gedea Biotech to address a significant unmet need for safe and effective treatments that support long-term vaginal health.
About Gedea Biotech
Gedea Biotech AB is a Swedish women’s health company on a mission to make a sustainable impact to global women’s health with a modern, antibiotic-free treatment for common vaginal infections that women can trust for long-term effect, available when they need it. Its lead product pHyph is CE-marked under the EU Medical Device Regulation (MDR) for the treatment of bacterial vaginosis and promotion of a healthy vaginal microbiome. Gedea is a spin out from Lund University and is based in Lund, Sweden.
Supported by the European Innovation Council
The European Innovation Council is Europe’s flagship innovation programme to identify, develop and scale up breakthrough technologies and game changing innovations The EIC has been established under the EU programme. It has a budget of €10.1 billion to support game changing innovations throughout the lifecycle from early stage research, to proof of concept, technology transfer, and the financing and scale up of start-ups and SMEs.
Press Kit
Click to download logos and images.
